None of the listed vaccines are authorized yet for public use.
1. In a phase 3 trial, Sanofi-GSK’s omicron-fighting vaccine candidate achieved a 72 percent efficacy against the variant — which the CDC reports makes up 100 percent of the nation’s COVID-19 cases — according to a June 24 press release.
Overall, the booster candidate showed a 64.7 percent efficacy against symptomatic infection and a 75.1 percent efficacy in people recovering from COVID-19. The trial found a “favorable safety and tolerability profile.”
2. Moderna plans to deliver tens of millions of its bivalent vaccine booster candidate this fall. The company said in a June 22 press release its booster increased antibodies 5.4-fold against omicron’s “sister variants,” BA.4 and BA.5.
The vaccine-maker said it has shared data with regulators and has manufactured doses in anticipation of approval.
3. Sanofi-GSK’s COVID-19 booster candidate beat Pfizer’s results June 13, with Sanofi-GSK’s second generation resulting in 76.1 percent of study participants seeing at least a tenfold increase in neutralizing antibody titers. Pfizer’s booster came in second with 63.2 percent.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
